beta
Trial Radar AI

Showing clinical trials for Extensive-Stage Small-Cell Lung Cancer, Extensive Stage Lung Small Cell Cancer.

I can help you find clinical trials in specific locations and provide insights on health conditions and treatments.

With advanced mode, access powerful pre-screening tools, interactive data visualizations, customized email alerts for trial updates and more.

11 Results
 
Status (Default)
Not yet Recruiting, Recruiting, Active, Not Recruiting
×
 
Condition
Extensive-Stage Small-Cell Lung Cancer, Extensive Stage Lung Small Cell Cancer
×
 
Intervention
Tarlatamab
×
 
Study Title
Status
Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308) NCT06598306
Recruiting
Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment (DeLLphi-307) NCT06502977
Active, not recruiting
Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer NCT07423585
Recruiting
A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2 (START-lung) NCT07203053
Not yet recruiting
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab (DeLLphi-305) NCT06211036
Active, not recruiting
A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311) NCT07037758
Recruiting
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC) (DeLLphi-312) NCT07005128
Recruiting
First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) NCT05361395
Active, not recruiting
Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC) ((DeLLphi-310)) NCT06898957
Recruiting
Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer NCT07328490
Not yet recruiting
A Study of Hospital-at-Home for People Receiving Tarlatamab NCT06957314
Recruiting